Crinetics Pharmaceuticals Inc (CRNX)

$59.16

+1.35

(+2.34%)

Market is closed - opens 8 PM, 07 Nov 2024

Performance

  • $58.63
    $60.90
    $59.16
    downward going graph

    0.9%

    Downside

    Day's Volatility :3.73%

    Upside

    2.86%

    downward going graph
  • $25.75
    $60.04
    $59.16
    downward going graph

    56.47%

    Downside

    52 Weeks Volatility :57.11%

    Upside

    1.47%

    downward going graph

Returns

PeriodCrinetics Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
22.48%
1.4%
0.0%
6 Months
24.13%
3.8%
0.0%
1 Year
100.41%
15.3%
0.0%
3 Years
112.73%
11.4%
-27.4%

Highlights

Market Capitalization
5.2B
Book Value
$10.47
Earnings Per Share (EPS)
-3.76
Wall Street Target Price
71.31
Profit Margin
0.0%
Operating Margin TTM
-20747.62%
Return On Assets TTM
-28.27%
Return On Equity TTM
-47.66%
Revenue TTM
1.4M
Revenue Per Share TTM
0.02
Quarterly Revenue Growth YOY
-59.599999999999994%
Gross Profit TTM
-125.5M
EBITDA
-276.2M
Diluted Eps TTM
-3.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.69
EPS Estimate Next Year
-3.86
EPS Estimate Current Quarter
-0.86
EPS Estimate Next Quarter
-0.88

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Crinetics Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
18
17
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 20.54%

Current $59.16
Target $71.31

Technicals Summary

Sell

Neutral

Buy

Crinetics Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
14.3%
24.13%
100.41%
112.73%
209.09%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
NA
NA
NA
-3.69
-0.48
-0.28
NA
10.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
Buy
$5.1B
209.09%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Crinetics Pharmaceuticals Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 640.0K → 399.0K (in $), with an average decrease of 37.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 8 quarters, -40.39M → -74.05M (in $), with an average decrease of 9.1% per quarter

Institutional Holdings

  • BlackRock Inc

    6.92%
  • Driehaus Capital Management LLC

    6.79%
  • Wellington Management Company LLP

    5.13%
  • Vanguard Group Inc

    5.01%
  • T. Rowe Price Associates, Inc.

    4.89%
  • EcoR1 Capital, LLC

    4.62%

Corporate Announcements

  • Crinetics Pharmaceuticals Inc Earnings

    Crinetics Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

neuropeptide receptor targeted therapeutics for the treatment of endocrine diseases and cancers. we are driven by a passion for drug-hunting and tempered by a post-recession startup culture. our goal is to create new therapeutics that can make a meaningful difference in the lives of our patients.

Organization
Crinetics Pharmaceuticals Inc
Employees
290
CEO
Dr. R. Scott Struthers Ph.D.
Industry
Health Technology

FAQs